OBJECTIVES: The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1) level as a predictor of future acute coronary events in patients with chronic coronary heart disease (CHD). BACKGROUND: Increased sICAM-1 concentration has been shown to be associated with the incidence of CHD in healthy persons. Its significance in patients with CHD has been scarcely investigated. METHODS: We designed a prospective, nested case-control study. Sera were collected from patients with CHD enrolled in a secondary prevention trial that evaluated the efficacy of bezafibrate in reducing coronary events. We measured baseline sICAM-1 concentration in the sera of patients who developed subsequent cardiovascular events (cases: n = 136) during follow-up (mean: 6.2 years) and in age- and gender-matched controls (without events: n = 136). RESULTS: Baseline serum concentrations of sICAM-1 were significantly higher in cases versus controls (375 vs. 350 ng/ml; p < 0.05). Each 100 ng/ml increase in sICAM-1 concentration was associated with 1.27 (95% confidence interval [CI]: 1.00 to 1.63) higher relative odds of coronary events. Soluble ICAM-1 concentration in the highest quartile (>394 ng/ml) was associated with significantly higher odds of coronary events (compared with the lowest quartile), even after multivariate adjustment (2.31, 95% CI: 1.02 to 5.50). After adding fibrinogen and total white blood cell count to the multivariate model, the relative odds were 2.12 (95% CI: 0.88 to 5.35) and 2.70 (95% CI: 1.10 to 7.05), respectively. CONCLUSIONS: Elevated sICAM-1 concentration in CHD patients is associated with increased risk of future coronary events independent of other traditional risk factors.
OBJECTIVES: The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1) level as a predictor of future acute coronary events in patients with chronic coronary heart disease (CHD). BACKGROUND: Increased sICAM-1 concentration has been shown to be associated with the incidence of CHD in healthy persons. Its significance in patients with CHD has been scarcely investigated. METHODS: We designed a prospective, nested case-control study. Sera were collected from patients with CHD enrolled in a secondary prevention trial that evaluated the efficacy of bezafibrate in reducing coronary events. We measured baseline sICAM-1 concentration in the sera of patients who developed subsequent cardiovascular events (cases: n = 136) during follow-up (mean: 6.2 years) and in age- and gender-matched controls (without events: n = 136). RESULTS: Baseline serum concentrations of sICAM-1 were significantly higher in cases versus controls (375 vs. 350 ng/ml; p < 0.05). Each 100 ng/ml increase in sICAM-1 concentration was associated with 1.27 (95% confidence interval [CI]: 1.00 to 1.63) higher relative odds of coronary events. Soluble ICAM-1 concentration in the highest quartile (>394 ng/ml) was associated with significantly higher odds of coronary events (compared with the lowest quartile), even after multivariate adjustment (2.31, 95% CI: 1.02 to 5.50). After adding fibrinogen and total white blood cell count to the multivariate model, the relative odds were 2.12 (95% CI: 0.88 to 5.35) and 2.70 (95% CI: 1.10 to 7.05), respectively. CONCLUSIONS: Elevated sICAM-1 concentration in CHD patients is associated with increased risk of future coronary events independent of other traditional risk factors.
Authors: Fen Wu; Farzana Jasmine; Muhammad G Kibriya; Mengling Liu; Oktawia Wójcik; Faruque Parvez; Ronald Rahaman; Shantanu Roy; Rachelle Paul-Brutus; Stephanie Segers; Vesna Slavkovich; Tariqul Islam; Diane Levy; Jacob L Mey; Alexander van Geen; Joseph H Graziano; Habibul Ahsan; Yu Chen Journal: Am J Epidemiol Date: 2012-04-24 Impact factor: 4.897
Authors: Valderilio Feijó Azevedo; J R Faria-Neto; Andrea Stinghen; Pedro G Lorencetti; Wagner P Miller; Beatriz P Gonçalves; Carla C Szyhta; Roberto Pecoits-Filho Journal: Rheumatol Int Date: 2013-01-08 Impact factor: 2.631
Authors: Christopher M Celano; Eleanor E Beale; Scott R Beach; Arianna M Belcher; Laura Suarez; Shweta R Motiwala; Parul U Gandhi; Hanna Gaggin; James L Januzzi; Brian C Healy; Jeff C Huffman Journal: Psychosom Med Date: 2017-04 Impact factor: 4.312
Authors: M S O'Neill; A Veves; J A Sarnat; A Zanobetti; D R Gold; P A Economides; E S Horton; J Schwartz Journal: Occup Environ Med Date: 2006-12-20 Impact factor: 4.402
Authors: Shohreh F Farzan; Elizabeth B Brickley; Zhigang Li; Diane Gilbert-Diamond; Anala Gossai; Yu Chen; Caitlin G Howe; Thomas Palys; Margaret R Karagas Journal: Environ Res Date: 2017-04-12 Impact factor: 6.498
Authors: Xiao Xia Li; Jian Ping Liu; Jin Quan Cheng; Sheng Hong Han; Yi Jie Geng; Sheng Wei; Shi Tong Gao; Da Na Huang; Shao Fa Nie Journal: Mol Biol Rep Date: 2008-09-14 Impact factor: 2.316
Authors: Jing Li; Cong Wang; Wenjing Wang; Lingzi Liu; Qingqing Zhang; Jun Zhang; Bo Wang; Shujing Wang; Li Hou; Chuanzhou Gao; Xiao Yu; Lei Sun Journal: Front Cardiovasc Med Date: 2021-03-11
Authors: J Skrha; J Soupal; G Loni Ekali; M Prázný; M Kalousová; J Kvasnička; L Landová; T Zima; J Skrha Journal: J Diabetes Res Date: 2013-03-10 Impact factor: 4.011
Authors: Philip F Binkley; Glen E Cooke; Amanda Lesinski; Mackenzie Taylor; Min Chen; Bryon Laskowski; W James Waldman; Maria E Ariza; Marshall V Williams; Deborah A Knight; Ronald Glaser Journal: PLoS One Date: 2013-01-17 Impact factor: 3.240